Luke Halpern, Assistant Editor

Multiple FDA-approved drugs without lipid-lowering indications were identified to have potential lipid-lowering properties.

Older adults in the United States continue to be burdened with disproportionate rates of community-acquired pneumonia hospitalizations, including due to serotypes covered in the recently approved V116 vaccine.

Designed for use in Celiac disease, larazotide was found to hasten resolution of multisystem inflammatory syndrome symptoms in children with the condition.

Inclisiran was found to have a lower risk causing new-onset diabetes compared with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies.

Secretary Robert F. Kennedy Jr announced the cancellation of 22 mRNA vaccine technology investments, alleging the vaccines lacked effectiveness against respiratory diseases.

New research highlights a surge in pediatric pneumococcal pneumonia cases post COVID-19, urging a shift toward supportive treatment strategies.

Continuing a trend observed since the end of the COVID-19 pandemic, vaccine coverage among kindergartners declined in the 2024-2025 school year, according to CDC data.

In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).

Sundar Jagannath, MBBS, highlights pharmacists’ expanding role in managing linvoseltamab’s immunologic profile, supporting adverse event response, and advancing multiple myeloma care.

The approval builds upon concizumab’s previous December 2024 clearance and allows for treatment in patients with hemophilia A or B, both with or without inhibitors.

By targeting aldosterone in a 2-dose regimen, baxdrostat effectively lowers mean seated systolic blood pressure in patients with difficult-to-treat hypertension.

Both vaccine and nonvaccine serotypes were identified as being resistant to critical antimicrobial treatments for pneumococcal disease.

Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients.

Hospitalized older adults infected with SARS-CoV-2 had faster declines in executive function and memory compared with both uninfected and nonhospitalized infected patients.

Namrata Shah, MD, highlights lenacapavir’s ease of use, long-acting protection, and the vital role pharmacists play in expanding equitable HIV prevention access.

Tildrakizumab 100 mg shows significant efficacy in treating psoriatic arthritis, achieving key clinical trial end points and offering hope for patients.

Data from a retrospective study of adults in France found the highest incidence of pneumococcal disease in patients with the highest risk underlying medical conditions.

Sepiapterin treatment allowed patients to liberalize their diet while reaching or exceeding recommended daily protein allowances in patients living with phenylketonuria.

Durvalumab continues to demonstrate efficacy in a variety of cancers, with new data from the phase 3 MATTERHORN trial solidifying its use with chemotherapy in gastric cancer.

With cuts to the Department of Health and Human Services incoming, efforts to research, surveil, and prevent infections of Clostridioides difficile could be derailed.

Namrata Shah, MD, discusses the groundbreaking efficacy and patient-centered potential of twice-yearly lenacapavir for HIV preexposure prophylaxis (PrEP), supported by pivotal data from the PURPOSE trials.

Conversely, Medicaid enrollees experienced widening gaps of pneumococcal vaccination uptake, likely driven by socioeconomic obstacles.

Sundar Jagannath, MD, MBBS, explains how linvoseltamab showed strong efficacy and tolerability in the LINKER-MM1 trial, making it an appealing option for older patients with relapsed or refractory multiple myeloma (MM).

High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).

The approval represents a major advancement for patients with moderate-to-severe chronic hand eczema, as delgocitinib becomes the first treatment available for this population in the US.

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

Adam James, PharmD, and Chris Altman, PharmD, explain how pharmacists can build trust and reduce vaccine hesitancy by clearly communicating thimerosal’s limited role in today’s immunizations and addressing patient concerns with empathy and education.

Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.

Debra Patt, MD, PhD, MBA, and Houston Holmes, MD, explore how the removal of risk evaluation and management strategies (REMS) for chimeric antigen receptor (CAR) T-cell (CAR T) therapies can improve health equity, expand access in community settings, and elevate the pharmacist’s role in care coordination.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.